Johnson & Johnson (NYSE:JNJ) ranks among the 14 safe stocks to buy now for a starter stock portfolio. On March 2, BofA ...

The fair value estimate for Johnson & Johnson has been adjusted from US$232.50 to US$237.29 per share, a small move that ...

Johnson & Johnson (JNJ) announced on Friday the achievement of a primary safety endpoint in a Phase 1 trial for a drug ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent ...

Volatility is again picking up, and it’s a good idea to focus more on safety. There’s no better way to do so than to buy ...

Johnson & Johnson’s position as a diversified healthcare leader continues to attract attention within equity markets. Through ...

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.

Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $21.9 ...

Johnson & Johnson (JNJ) units will pay $65M to settle a Tracleer antitrust class action over alleged delays to generic competition. Read more here.

Johnson & Johnson (JNJ), Chevron (CVX), Realty Income (O), Broadcom (AVGO), and Agree Realty (ADC) for income investors.

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

March 4 (Reuters) - Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either ...